PMID- 32234251
OWN - NLM
STAT- MEDLINE
DCOM- 20210929
LR  - 20210929
IS  - 2529-993X (Electronic)
IS  - 2529-993X (Linking)
VI  - 39
IP  - 2
DP  - 2021 Feb
TI  - Neuropsychiatric adverse effects of dolutegravir in real-life clinical practice.
PG  - 78-82
LID - S0213-005X(20)30052-5 [pii]
LID - 10.1016/j.eimc.2020.02.018 [doi]
AB  - INTRODUCTION: Integrase inhibitors and especially dolutegravir (DTG) are placed 
      as a first-line antiretroviral treatment for their efficacy and safety. Although 
      in the pivotal trials the rate of adverse effects (AEs) was low (2-3%), in 
      real-life studies it appears to be higher, especially neuropsychiatric AEs. The 
      objective is to determine the percentage of AEs and discontinuation of DTG in our 
      site and the relationship with the psychiatric background. METHODS: Retrospective 
      descriptive study of patients starting DTG from 2015 to 2017. Discontinuation of 
      treatment, AEs and previous psychiatric pathology were recorded. Follow-up is 
      carried out since the beginning of the treatment, and hospitalizations and 
      emergency room and primary care visits were registered. The study was authorized 
      by the Ethics Committee for Clinical Research of Aragon. RESULTS: Two hundred and 
      eighty-three patients were included, between 11 and 87 years old, 70% male. 21% 
      were naive. 24% of the patients discontinued treatment with DTG, 10% due to AEs. 
      Neuropsychiatric AEs were detected in 5%. This group of patients had a more 
      frequent previous psychiatric history (62 vs. 41%; P=.002) than the ongoing 
      treatment group and they needed more visits to primary care (18.8 vs. 8.4%; 
      P=.016) and emergency room (8,7 vs. 3.3%; P=.061). CONCLUSION: Patients who 
      discontinued treatment with DTG had more psychiatric history. Although more 
      studies are required, it is necessary to assess this background before starting 
      treatment with integrase inhibitors. Symptoms such as anxiety, insomnia or 
      depression can be DTG AEs more frequently than expected. Being identified by 
      primary care and emergency physicians could avoid the unnecessary prescription of 
      other medications.
CI  - Copyright (c) 2020 Elsevier Espana, S.L.U. and Sociedad Espanola de Enfermedades 
      Infecciosas y Microbiologia Clinica. All rights reserved.
FAU - Povar-Echeverria, Marina
AU  - Povar-Echeverria M
AD  - Medicina Interna, Hospital Universitario Miguel Servet, Zaragoza, Espana. 
      Electronic address: mpovar@salud.aragon.es.
FAU - Comet-Bernad, Macarena
AU  - Comet-Bernad M
AD  - Servicio de Farmacia Hospitalaria, Hospital Universitario Miguel Servet, 
      Zaragoza, Espana.
FAU - Gasso-Sanchez, Amalia
AU  - Gasso-Sanchez A
AD  - Servicio de Farmacia Hospitalaria, Hospital Universitario Miguel Servet, 
      Zaragoza, Espana.
FAU - Ger-Buil, Adriana
AU  - Ger-Buil A
AD  - Medicina Interna, Hospital Universitario Miguel Servet, Zaragoza, Espana.
FAU - Navarro-Aznarez, Herminia
AU  - Navarro-Aznarez H
AD  - Servicio de Farmacia Hospitalaria, Hospital Universitario Miguel Servet, 
      Zaragoza, Espana.
FAU - Martinez-Alvarez, Rosa
AU  - Martinez-Alvarez R
AD  - Medicina Interna, Subseccion de Enfermedades Infecciosas, Hospital Universitario 
      Miguel Servet, Zaragoza, Espana.
FAU - Arazo-Garces, Piedad
AU  - Arazo-Garces P
AD  - Medicina Interna, Subseccion de Enfermedades Infecciosas, Hospital Universitario 
      Miguel Servet, Zaragoza, Espana.
LA  - eng
LA  - spa
PT  - Journal Article
TT  - Efectos adversos neuropsiquiatricos de dolutegravir en la practica clinica real.
DEP - 20200328
PL  - Spain
TA  - Enferm Infecc Microbiol Clin (Engl Ed)
JT  - Enfermedades infecciosas y microbiologia clinica (English ed.)
JID - 101777541
RN  - 0 (Heterocyclic Compounds, 3-Ring)
RN  - 0 (Oxazines)
RN  - 0 (Piperazines)
RN  - 0 (Pyridones)
RN  - DKO1W9H7M1 (dolutegravir)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Child
MH  - Female
MH  - *HIV Infections/drug therapy
MH  - *HIV-1
MH  - Heterocyclic Compounds, 3-Ring
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Oxazines
MH  - Piperazines
MH  - Pyridones
MH  - Retrospective Studies
MH  - Young Adult
OTO - NOTNLM
OT  - Dolutegravir
OT  - Efectos adversos
OT  - Efectos adversos neuropsiquiatricos
OT  - HIV
OT  - Inhibidores de la integrasa
OT  - Integrase inhibitor
OT  - Neuropsychiatric adverse events
OT  - Side effects
OT  - Toxicidad
OT  - Toxicity
OT  - VIH
EDAT- 2020/04/03 06:00
MHDA- 2021/09/30 06:00
CRDT- 2020/04/03 06:00
PHST- 2019/10/27 00:00 [received]
PHST- 2020/02/07 00:00 [revised]
PHST- 2020/02/10 00:00 [accepted]
PHST- 2020/04/03 06:00 [pubmed]
PHST- 2021/09/30 06:00 [medline]
PHST- 2020/04/03 06:00 [entrez]
AID - S0213-005X(20)30052-5 [pii]
AID - 10.1016/j.eimc.2020.02.018 [doi]
PST - ppublish
SO  - Enferm Infecc Microbiol Clin (Engl Ed). 2021 Feb;39(2):78-82. doi: 
      10.1016/j.eimc.2020.02.018. Epub 2020 Mar 28.